Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company’s…
VIVOLTA, the medical electrospinning solutions provider, has signed a long-term partnership with Neurochase, the CNS (central nervous system) delivery platform specialist, to manufacture electrospun micro-catheters to deliver advanced therapies to…
Kanvas Biosciences, a spatial biology company, has unveiled clinical trial results at the 2024 Society for Immunotherapy of Cancer (SITC) meeting, showing the potential of fecal microbiota transplantation (FMT) in…
Brenus Pharma has announced the publication of a scientific article in Frontiers in Oncology detailing the results of its novel “off-the-shelf” cancer treatment. The company’s innovative platform replicates patients’ relapsing…
Baxter International Inc. (NYSE: BAX), a global leader in medical technology, today announced its financial results for the third quarter of 2024. “Baxter achieved strong performance in Q3 2024 as…
Care Access, a global clinical research company focused on advancing medicine, is hosting a Heart & Kidney Health Screening event in Houston, Texas. The initiative is designed to raise awareness…
Tempus AI, Inc. (NASDAQ: TEM), a leader in utilizing AI to advance precision medicine and patient care, announced today that nine abstracts have been accepted for presentation at the Society…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that it will present new data on a range of B-cell malignancies and treatments at the…
AstraZeneca and Amgen announced promising top-line results from the Phase III WAYPOINT trial, showing that Tezspire (tezepelumab) significantly reduced nasal polyp size and congestion in patients with chronic rhinosinusitis with…
Moderna announced that Health Canada has approved mRESVIA™ (Respiratory Syncytial Virus mRNA vaccine) for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older.…
Last fall, the Food and Drug Administration (FDA) recommended discontinuing the use of oral phenylephrine in over-the-counter (OTC) cold and cough products due to concerns over its effectiveness. This decision…
Royalty Pharma plc (Nasdaq: RPRX) announced an agreement to acquire a synthetic royalty on U.S. sales of Geron Corporation’s (Nasdaq: GERN) RYTELO, with a $125 million upfront cash payment. Approved…